Sulfacetamide Sodium (sulfacetamide sodium)
Ophthalmic Antibacterials Ophthalmic (Eye) Drops
Last reviewed · Source: First Databank (FDB) drug data
Overview
Sulfacetamide sodium is a sulfonamide antibacterial agent.
USES: This medication is used to treat bacterial eye infections (such as conjunctivitis). It belongs to a class of drugs known as sulfa antibiotics. Sulfacetamide works by stopping the growth of bacteria.
This medication treats only bacterial eye infections. It will not work for other types of eye infections. Using any antibiotic when it is not needed can cause it to not work for future infections.
Generic name: sulfacetamide sodium
Pronunciation: (SUL-fa-SEET-a-mide)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Sulfacetamide Sodium
Indications
The following indications are listed for Sulfacetamide Sodium:
- Bacterial Conjunctivitis
- Chlamydial Conjunctivitis
- Trachoma
Also known as: Chronic Contagious Microbial Inflammation, Conjunctivitis Caused By Chlamydia Trachomatis, Contagious Granular Conjunctivitis, Egyptian Ophthalmia, Granular Lids, Granular Ophthalmia, Inflammation Of The Conjunctiva Due To Bacteria.
Dosing
Dosage of sulfacetamide sodium is expressed in terms of the salt.
Dosage of fixed-combination preparations containing sulfacetamide sodium and prednisolone acetate or prednisolone sodium phosphate are expressed in terms of the salts.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Sulfacetamide 10% Eye Drops | Maintenance | Instill 1 drop into affected eye(s) by ophthalmic route every 2-3 hours during the day and less frequently at night. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Sulfacetamide 10% Eye Drops | Maintenance | Instill 1 drop into affected eye(s) by ophthalmic route every 2-3 hours during the day and less frequently at night. |
Drug interactions
Sulfacetamide sodium is incompatible with preparations containing silver. (See Chemistry and Stability: Stability)
Because the antibacterial activity of sulfonamides involves competitive inhibition of p-aminobenzoic acid (PABA), antagonism may occur between sulfonamides and local anesthetics that are PABA derivatives.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Ophthalmic Sodium Sulfacetamide/Ophthalmic Silver
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Ophthalmic sodium sulfacetamide and ophthalmic silver are physically incompatible.(1)
CLINICAL EFFECTS: Concurrent application of ophthalmic sodium sulfacetamide and ophthalmic silver preparations may result in decreased clinical effectiveness of the products.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Avoid using ophthalmic silver preparations in the same eye as ophthalmic sodium sulfacetamide products.(1)
DISCUSSION: Ophthalmic sodium sulfacetamide and ophthalmic silver are physically incompatible.(1)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Hemoglobin H disease
- Hemolytic anemia from pyruvate kinase and g6PD deficiencies
- Porphyria
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Erythema
- Pruritus of skin
- Skin inflammation
- Skin irritation
- Skin rash
Rare or Very Rare
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency anemia
Rare or Very Rare
- Eyelid edema
Precautions
No enhanced messaging available.
No enhanced messaging available.
Animal reproduction studies have not been performed using sulfacetamide ophthalmic preparations.
There are no adequate and well-controlled studies using sulfonamide ophthalmic preparations in pregnant women, and it is not known whether topically applied sulfonamides can cause fetal harm when administered to pregnant women. Use of oral sulfonamides in pregnant women at term may result in kernicterus in neonates.
Sulfacetamide sodium ophthalmic preparations, including fixed-combination preparations containing sulfacetamide sodium and a corticosteroid, should be used during pregnancy only if potential benefits justify potential risks to the fetus.
Systemically administered sulfonamides are capable of producing kernicterus in breast-fed infants.
Because of the potential for development of kernicterus in neonates, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Bacterial conjunctivitis | ||
| H10.02 | ICD10CM | Other mucopurulent conjunctivitis |
| H10.021 | ICD10CM | Other mucopurulent conjunctivitis, right eye |
| H10.022 | ICD10CM | Other mucopurulent conjunctivitis, left eye |
| H10.023 | ICD10CM | Other mucopurulent conjunctivitis, bilateral |
| H10.029 | ICD10CM | Other mucopurulent conjunctivitis, unspecified eye |
| H10.3 | ICD10CM | Unspecified acute conjunctivitis |
| H10.30 | ICD10CM | Unspecified acute conjunctivitis, unspecified eye |
| H10.31 | ICD10CM | Unspecified acute conjunctivitis, right eye |
| H10.32 | ICD10CM | Unspecified acute conjunctivitis, left eye |
| H10.33 | ICD10CM | Unspecified acute conjunctivitis, bilateral |
| Chlamydial conjunctivitis | ||
| A74.0 | ICD10CM | Chlamydial conjunctivitis |
| Trachoma | ||
| A71 | ICD10CM | Trachoma |
| A71.0 | ICD10CM | Initial stage of trachoma |
| A71.1 | ICD10CM | Active stage of trachoma |
| A71.9 | ICD10CM | Trachoma, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.